Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

11
243
3
4

Year Published

2002
2002
2019
2019

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 121 publications
(261 citation statements)
references
References 0 publications
11
243
3
4
Order By: Relevance
“…62,71 Orlistat had inconsistent effects on glycemic control: modest but significantly greater reductions in fasting blood glucose (0.1-1.7 mmol/l) than diet-only therapy in six studies, [60][61][62][63]67,68 but no difference in two studies. 65,66 The greatest improvements in glycemic control occurred in subjects with type 2 diabetes. 67,68 There were no significant effects of sibutramine therapy compared to diet-only therapy on lipids and glycemic control, but sibutramine was associated with higher systolic (1-4 mmHg) and diastolic (2-4 mmHg) blood pressure, 72,73,75,76 including subjects with treated hypertension.…”
Section: Jd Douketis Et Almentioning
confidence: 99%
“…62,71 Orlistat had inconsistent effects on glycemic control: modest but significantly greater reductions in fasting blood glucose (0.1-1.7 mmol/l) than diet-only therapy in six studies, [60][61][62][63]67,68 but no difference in two studies. 65,66 The greatest improvements in glycemic control occurred in subjects with type 2 diabetes. 67,68 There were no significant effects of sibutramine therapy compared to diet-only therapy on lipids and glycemic control, but sibutramine was associated with higher systolic (1-4 mmHg) and diastolic (2-4 mmHg) blood pressure, 72,73,75,76 including subjects with treated hypertension.…”
Section: Jd Douketis Et Almentioning
confidence: 99%
“…The effect of changes in BMI on utilities was calculated by Hakim et al 20 and relied on original data collected by Hauptman et al 21 According to those findings, every one-unit reduction in BMI per year increases the utility value by 0.0285 in obese diabetic patients (base-case analysis) and by 0.017 in obese nondiabetic patients (value that was used for the sensitivity analysis). 2.…”
Section: Cost-effectiveness Analysismentioning
confidence: 99%
“…Orlistat, which is a powerful lipase inhibitory drug, exerts its effects by reducing lipid absorption from dietary fat. Although orlistat reduces body weight, side effects such as flatulence with discharge, increased defecation, and fecal incontinence with increasing fecal lipid excretion are known (Hauptman et al, 2000;Hvizdos and Markham, 1999). WLE significantly decreased the body weight of rats despite the promotion of lipid absorption.…”
Section: Resultsmentioning
confidence: 99%